對於全球罕見病藥物開發商來說，中國及其14億人口可能提供相對較多的此類疾病患者。從該國試驗中獲得的臨床數據也可用於説明加快美國或歐洲的臨床研究。
May
16
© 2024 NGGT Inc. All Rights Reserved. Terms of Use | Privacy Policy | Accessibility Statement
Website developed by Insight Designs
Website developed by Insight Designs
Comments are closed.